… Hereditary angioedema therapy relies on treatment of acute attacks, and short- and long-term …
with C1-INH concentrate, icatibant or ecallantide; tranexamic acid or androgens are …

… acute treatment for angioedema has been fundamental in reducing the burden of illness for
patients with hereditary angioedema (HAE… The plasma kallikrein inhibitor ecallantide and the …

… Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema
attacks. J Allergy Clin Immunol Pract (2015) 3(2):206–12. doi:10.1016/j.jaip.2014.09.001 …

Modern management of hereditary angioedema (HAE) includes managing the acute attack, …
that place the patient at risk of an attack, and long-term management for those where the …

… on the management of hereditary angioedema (HAE) and … , ecallantide (30 mg subcutaneous)
was tested specifically in patients with hereditary angioedema suffering laryngeal attacks …

… , so patients are unable to treat acute attacks at home.Additionally, finding a medical facility
at … demonstrate efficacy of icatibant in treating acute attacks in patients with the PLG mutation.…

… to treat severe life-threatening attacks … ecallantide in patients with hereditary angioedema
[Citation40,Citation41,Citation44]. The results for 30 mg subcutaneous injection of ecallantide …

… Ecallantide was approved as acute treatment in 2009, in the … severe as well as 30.2% of very
severe attacks were treated … shorter in self-treated than in HCP-treated attacks (1.5 vs. 2.4 h; …

… 0.786 for ecallantide. At a mean annual attack rate of 26.9, cost per QALY was $402,769 for
rhC1-INH, $475,942 for icatibant, $462,275 for pdC1-INH, and $666,153 for ecallantide. Re-…

… -controlled trials of ecallantide for acute attacks of hereditary angioedema. Expert Rev Clin
… antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 …